Team identifies factors for COVID-19 vaccine protection
A comparison of immune correlates of AstraZeneca’s Phase II/III COVID-19 vaccine trial shows what antibodiy titer is required to prevent symptomatic disease.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1259 entries already.
Entries by Thomas Gabrielczyk
EIF supports translational med with 25m
/in News/by Thomas GabrielczykThe EIF has invested 25m in the Prague-based i&i Biotech Fund I to boost biomedical tech transfer in Austria and Eastern Europe.
AstraZeneca puts 307m in Irish Alexion plant
/in News/by Thomas GabrielczykFollowing the $39bn Alexion buy-out completed in July, AstraZeneca plc announced it will invest 307m in the company’s producion site near Dublin.
Touchlight extends funding round to boost DNA vector manufacture
/in News/by Thomas GabrielczykUK-based DNA synthesis specialist Touchlight Ltd has extended a funding round to a current aggregate total of US $125m.
Swiss Biotech Day shows great biopharma ambitions
/in News/by Thomas GabrielczykThe Swiss biopharmaceutical industry is on the verge of record growth: This was demonstrated at the live Swiss Biotech Day in Basel.
EuropaBio lobbies for better Orphan Drug rules
/in News/by Thomas GabrielczykEuropaBio has responded to the European Commissions public consultation on the Orphan Medicinal Products (OMPs) and Paediatrics Regulations.
Cardior bags 64m in Series B Financing
/in News/by Thomas GabrielczykCardior Pharmaceuticals GmbH is funding a Phase II trial with lead candidate CDR132L against mi-R132-induced heart failure.
ERS Genomics and Cellular Engineering Technologies collaborating
/in News/by Thomas GabrielczykERS Genomics and Cellular Engineering Technologies have entered into a CRISPR-Cas9 license agreement.
Visus Therapeutics cashes in 20m from LSP
/in News/by Thomas GabrielczykVisus Therapeutics has baged a 20m stock financing to advance development of Brimochol for presbyopia